|
|
|
|
| LEADER |
04951nmm a2200409 u 4500 |
| 001 |
EB000619573 |
| 003 |
EBX01000000000000000472655 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781461235088
|
| 100 |
1 |
|
|a Talwar, G. P.
|
| 245 |
0 |
0 |
|a Progress in Vaccinology
|h Elektronische Ressource
|c by G. P. Talwar
|
| 250 |
|
|
|a 1st ed. 1989
|
| 260 |
|
|
|a New York, NY
|b Springer New York
|c 1989, 1989
|
| 300 |
|
|
|a XX, 483 p
|b online resource
|
| 505 |
0 |
|
|a I Opening Remarks -- 1. Vaccinology: The Two Revolutions -- II Public Health Perspective—The Present Scene -- 2. Vaccinology and the Goal of Health for All -- 3. Toward Universal Immunization: 1990 -- 4. New and Improved Techniques for Vaccine Production -- 5. Transfer of Vaccine Production to the Developing World: Rabies Vaccine -- 6. Policy for Developing Countries for Storage, Distribution, and Use of Essential Vaccines for Immunoprophylaxis -- III Environmental Factors Modulating The Efficacy of The Vaccine -- 7. Immunity in Tuberculosis: Environmental Versus Intrinsic Factors Modulating the Immune Responsiveness to Mycobacteria -- 8. Geographic Variation in Vaccine Efficacy: The Polio Experience -- IV Hepatitis -- 9. Molecular Immunology of Viral Antigens in Hepatitis B Vaccinations -- 10. Biologic Significance of Pre-S Antigen and Anti-Pre-S Antibodies in Hepatitis B Virus Infection -- 11. Enterically Transmitted Hepatitis Viruses: Prospects for Control --
|
| 505 |
0 |
|
|a VI Filariasis -- 24. Importance of Antibody Class in Helminth Infections -- 25. Immunodiagnosis of Filariasis -- VII Veterinary Vaccines -- 26. Development, Production, and Application of Vaccines in Foot-and-Mouth Disease Control in India -- 27. Cell Culture Vaccine Against Bovine Tropical Theileriosis -- VIII Leprosy -- 28. Present Approaches to Immunotherapy and Immunoprophylaxis for Leprosy -- 29. Armadillo-Derived Killed M. leprae: Candidate Vaccine Against Leprosy -- 30. Mycobacterium w: Candidate Vaccine Against Leprosy with Antigens Cross-Reactive with Three Major Protein Antigens of Mycobacterium leprae -- 31. Molecular Approaches to Developing a Vaccine for Leprosy, -- 32. Immunodiagnosis of Leprosy -- 33. Immunodiagnostic Approaches to the Detection of M. leprae Infection in Leprosy -- 34. Serological Survey of Leprosy Using a Monoclonal Antibody-Based Immunoassay and Phenolic Glycolipid ELISA -- IX Malaria and Leishmaniasis --
|
| 505 |
0 |
|
|a 12. Immunological Characterization of a Viral Agent Involved in Epidemic and Sporadic Non-A Non-B Hepatitis -- V Gastrointestinal Infections -- 13. Attenuated Oral Typhoid Vaccine Ty 21a -- 14. Oral B Subunit—Whole Cell Vaccine Against Cholera: From Basic Research to Successful Field Trial -- 15. Prospects of Immunization Against Cholera by Adhesive Antigen -- 16. Protective Antigens of Vibrio cholerae -- 17. Rationale for the Development of a Rotavirus Vaccine for Infants and Young Children -- 18. Mucosal Immunity in the Gastrointestinal Tract in Relation to ETEC Vaccine Development -- 19. Shigella Vaccines -- 20. DNA Sequence Homology Among Genes of Shigella spp. and Enteroinvasive Escherichia coli.. -- 21. Mucosal and Acquired Immunity in Giardiasis and Its Relation to Diarrhea and Malabsorption -- 22. Immunology of Entamoebahistolytica in Human and Experimental Hosts -- 23. Molecular Comparisons Among Entamoeba histolytica Strains Using DNA and Protein Profiles --
|
| 505 |
0 |
|
|a 35. Antisporozoite Malaria Vaccine Development Based on Circumsporozoite Protein -- 36. Malaria Sporozoite Vaccine Development: Recent Progress -- 37. Community-Based Integrated Vector Control of Malaria in India -- 38. Leishmaniasis and Malaria: New Tools for Epidemiological Analysis -- X New Approaches to Vaccinology -- 39. Vaccinia Virus Expression Vectors -- 40. Vaccinia Recombinants Expressing Foreign Antigens: Antiviral and Antitumor Immunity -- 41. Liposomes as Carriers of Vaccines -- 42. A Short Primer on Vaccine Design: Focus on the Interrelatedness of Antigenic Determinants Addressing Various Lymphocyte Sub-populations -- 43. Next Steps in the Evolution of Vaccinology
|
| 653 |
|
|
|a Internal medicine
|
| 653 |
|
|
|a Life sciences
|
| 653 |
|
|
|a Immunology
|
| 653 |
|
|
|a Internal Medicine
|
| 653 |
|
|
|a Life Sciences
|
| 653 |
|
|
|a Allergy
|
| 653 |
|
|
|a Gastroenterology
|
| 653 |
|
|
|a Medical Microbiology
|
| 653 |
|
|
|a Allergology
|
| 653 |
|
|
|a Medical microbiology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Progress in Vaccinology
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4612-3508-8
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4612-3508-8?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 570
|
| 520 |
|
|
|a Vaccines have historically been considered to be the most cost-effective method for preventing communicable diseases. It was a vaccine that en abled global eradication of the dreaded disease smallpo.
|